Structural complexity is one of the defining challenges of biopharmaceutical development. Unlike small-molecule drugs, large protein therapeutics (monoclonal antibodies, fusion proteins, peptide therapeutics, and biosimilars) are heterogeneous by nature, subject to a wide range of post-translational modifications that can influence…